Dengue human infection models supporting drug development.


Whitehorn, J; Van, VC; Simmons, CP; (2014) Dengue human infection models supporting drug development. The Journal of infectious diseases, 209 Suppl 2. S66-70. ISSN 0022-1899 DOI: 10.1093/infdis/jiu062

[img]
Preview
Text - Published Version
License:

Download (104Kb) | Preview

Abstract

Dengue is a arboviral infection that represents a major global health burden. There is an unmet need for effective dengue therapeutics to reduce symptoms, duration of illness and incidence of severe complications. Here, we consider the merits of a dengue human infection model (DHIM) for drug development. A DHIM could allow experimentally controlled studies of candidate therapeutics in preselected susceptible volunteers, potentially using smaller sample sizes than trials that recruited patients with dengue in an endemic country. In addition, the DHIM would assist the conduct of intensive pharmacokinetic and basic research investigations and aid in determining optimal drug dosage. Furthermore, a DHIM could help establish proof of concept that chemoprophylaxis against dengue is feasible. The key challenge in developing the DHIM for drug development is to ensure the model reliably replicates the typical clinical and laboratory features of naturally acquired, symptomatic dengue.

Item Type: Article
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Clinical Research
PubMed ID: 24872399
Web of Science ID: 337063800007
URI: http://researchonline.lshtm.ac.uk/id/eprint/1775889

Statistics


Download activity - last 12 months
Downloads since deposit
343Downloads
292Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item